`April 2007 - February 2015
`
`M arket Definition
`This is UCB defined AED market basket (aligned with the Vimpat M onthly Business Review Report)
`
`Factors have been applied to all products with AED indication
`
`Argentum Pharm. v. Research Corp. Techs., IPR2016-00204
`RCT EX. 2136 - 1/3
`
`
`
`AED Market Yearly TRx Volume & Market Share - April 2007 ,.., February 2015
`
`UCB Defined AED Products
`Aotiom
`BANZEL
`OEPAKOTE
`OEPAKOTE P.eneric
`DEPAKOTE-ER
`DEPAKOTE-ER generic
`DILANTIN
`DILANTIN generic
`FYCOMPA
`KEPPRA-IR
`KEPPRA·IR ~eneric
`KEPPRA-XR
`KEPPRA-XR R:eneric
`LAM I CT AL
`LAMICTAL P:eneric
`LAMICTAL-XR
`LAMICTAL·XR GENERIC
`LVRICA
`NEURONTIN
`NEURONTIN generic
`POTIGA
`SASRIL
`TEGRETOL
`TEGRETO L generic
`TEGRETOL-XR
`TEGRETOL-XR 1?eneric
`TOP AMAX
`TOPAMAX r.eneric
`TROKENDI XR
`TRILEPTAL
`TRILEPTAL 2eneric
`VIMPAT -taken as 100%
`ZONEGRAN
`ZONEGRAN 1teneric
`TOPIRAMATE ER
`QUDEXVXR
`lamotrir.ine ODT
`Active Pac/Gabapen
`Total
`
`Aor 2007 • Dec 2007
`
`2008
`
`TRx Volume
`2009
`2010
`
`2011
`
`2012
`
`2013
`
`2.470,031
`205.136
`1,623,762
`
`1,324,361
`2,909,752
`
`2,749,793
`
`2,395,637
`694,528
`2,206.333
`1.138
`1,537,122
`3,737,603
`
`39,144
`448,952
`1.725,242
`702 ,096
`731,946
`1.336,084
`3,550,487
`
`68,765
`269,653
`1,831,481
`293,430
`940,794
`1,174,912
`3,370,705
`
`4,074,242
`267,524
`14,067
`
`1,121.857
`3,328,124
`256,602
`
`576,284
`4,453,067
`359,398
`
`2 373 167
`19,927
`
`2 479,221
`539,815
`
`588,461
`1.553,933
`20,380
`
`381,784
`1,728,706
`117,584
`
`82,660
`223,037
`1,844,192
`194,348
`984.487
`1,021 ,795
`3,166,627
`
`465.305
`5,222,054
`331,010
`39,886
`312 ,756
`1,843,963
`170,440
`
`246,397
`49,981
`562,477
`
`391,579
`55,485
`820,089
`
`366,580
`49,250
`940,047
`
`345,640
`44,028
`1,082,478
`
`341,382
`32,259
`1,226,612
`
`206,490
`1,301.915
`562,053
`372,682
`2,354,454
`
`236,952
`1,702,783
`723,866
`480,747
`3,237,126
`
`1.411.228
`145,356
`
`524.118
`918,225
`
`58,649
`369,345
`
`64,295
`514,869
`
`2.737
`206,133
`1.676,449
`537,347
`613,506
`1.192,570
`1.071.073
`
`403,223
`992,830
`83,618
`56,735
`550,185
`
`16,342
`178,669
`1,667,926
`335,087
`748,133
`249,746
`1,636.330
`
`257,885
`1,096,995
`311,984
`52 ,124
`571,663
`
`29,440
`155,180
`1,630,542
`283,718
`743,947
`187,730
`1,722,786
`
`252,302
`1,111,644
`502 ,258
`46,267
`596,219
`
`86.421
`175,856
`1,856,602
`129,523
`1,005,827
`889,813
`3,013,269
`
`368,463
`5,912,051
`160,311
`198,317
`244,612
`1,965,404
`192,617
`
`328,105
`24,029
`1,422,914
`5,387
`22,102
`121,753
`1,684,848
`252 ,487
`748,138
`147,848
`1,841.658
`
`267,653
`1,112,126
`659,595
`38,817
`624,816
`
`94,994
`154,325
`1,943,080
`109,024
`1,046,793
`652,827
`2,974,633
`
`320,220
`6,624,941
`128.222
`258.302
`209,236
`2,131,576
`115,759
`128,375
`340,588
`19,436
`1,619,137
`13,106
`20,149
`99,858
`1,680,420
`233,880
`767,258
`125,112
`2,041.510
`4,707
`153.252
`1,249,954
`819,692
`33,858
`682,748
`
`21,316,955
`
`27,617,365
`
`24,145,592
`
`24,161,595
`
`24,764,843
`
`25,501,361
`
`26,796,970
`
`2014 Jan 2015 - Feb 2015
`6,728
`15.256
`101,361
`16,888
`135,254
`19,621
`321,835
`2,0U,149
`105,535
`15,581
`1,052,987
`167,848
`552,610
`81,329
`2,804,935
`426,742
`19,424
`5,442
`283,468
`41.408
`7,307.462
`1.223.661
`16,894
`111.875
`322,889
`57,938
`178,573
`26,189
`374,510
`2,261,356
`87,405
`12,356
`40,534
`215,518
`357,764
`57,893
`15,812
`2,258
`1,871,447
`320,143
`7,529
`988
`30,313
`2,942
`91,794
`13,710
`1,649,924
`255 ,360
`219,630
`34,040
`773,736
`123,714
`102,315
`13,973
`2,204,980
`364,584
`50,579
`13.117
`16,554
`116.092
`1,340,245
`221,425
`972,567
`171,842
`30,094
`4,433
`741,854
`123,920
`1,105
`811
`82
`311
`40
`0
`4,597,564
`
`28,145,920
`
`UCB Defined AED Products Aor 2007 ·Dec 2007
`Aptiom
`0.0%
`BANZEL
`0.0%
`DEPAKOTE
`11.6%
`DEPAKOTE 1teneric
`1.0%
`DEPAKOTE·ER
`7.6%
`OEPAKOTE-ER r.eneric
`0.0%
`OILANTIN
`6.2%
`DILANTIN l!eneri c
`13.6%
`FYCOMPA
`0.0%
`KEPPRA-IR
`12.9%
`KEPPRA-IR generic
`0.0%
`KEPPRA·XR
`0.0%
`KEPPRA·XR p,eneric
`0.0%
`LAMICTAL
`11.1%
`LAMICTAL 1teneric
`0.1%
`LAMICTAL·XR
`0.0%
`LAMICTAL-XR GENERIC
`0.0%
`LYRICA
`1.2%
`NEURONTI N
`0.2%
`NEURONTIN 1teneric
`2.6%
`POTIGA
`0.0%
`SABRIL
`0.0%
`TEGRETOL
`1.0%
`TEGRETOL generic
`6.1%
`TEGRETOL-XR
`2.6%
`TEGRETOL·XR P.eneric
`1.7%
`TOPAMA.X
`11.0%
`TOPAMAX Reneric
`0.0%
`TROKENDI XR
`0.0%
`TRILEPTAL
`6.6%
`TRILEPTAL r.ene ric
`0.7%
`VIMPAT -taken as 100%
`0.0%
`ZONEGRAN
`0.3%
`ZONEGRAN F,eneric
`1.7%
`TOPIRAMATE ER
`0.0%
`QUOEXYXR
`0.0%
`lamotrir,ine OOT
`0.0%
`Active Pac/Gabapen
`0.0%
`Tota l
`100.0%
`
`2008
`0.0%
`0.0%
`8.7%
`2.5%
`8.0%
`0.0%
`5.6%
`13.5%
`0.0%
`14.8%
`1.0%
`0.1%
`0.0%
`9.0%
`2.0%
`0.0%
`0.0%
`1.4%
`0.2%
`3.0%
`0.0%
`0.0%
`0.9%
`6.2%
`2.6%
`1.7%
`11.7%
`0.0%
`0.0%
`1.9%
`3.3%
`0.0%
`0.2%
`1.9%
`0.0%
`0.0%
`0.0%
`0.0%
`100.0%
`
`Market Share
`2009
`2010
`0.0%
`0.0%
`0.2%
`0.3%
`1.9%
`1.1%
`7.1%
`7.6%
`2.9%
`1.2%
`3.0%
`3.9%
`4.9%
`5.5%
`14.0%
`14.7%
`0.0%
`0.0%
`4.6%
`2.4%
`13.8%
`18.4%
`1.5%
`1.1%
`0.0%
`0.0%
`2.4%
`1.6%
`6.4%
`7.2 %
`0.1%
`0.5%
`0.0%
`0.0%
`1.5%
`1.4%
`0.2%
`0.2%
`4.5%
`3.9%
`0.0%
`0.0%
`0.0%
`0.1%
`0.9%
`0.7%
`6.9%
`6.9%
`1.4%
`2.2%
`3.1%
`2.5%
`4.9%
`1.0%
`4.4%
`6.8%
`0.0%
`0.0%
`1.7%
`1.1%
`4.1%
`4.5%
`0.3%
`1.3%
`0.2%
`0.2%
`2.4%
`2.3%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`100.0%
`100.0%
`
`2011
`0.0%
`0.3%
`0.9%
`7.4%
`0.8%
`4.0%
`4.1%
`12.8%
`0.0%
`1.9%
`21.1%
`1.3%
`0.2%
`1.3%
`7.4%
`0.7%
`0.0%
`1.4%
`0.1%
`5.0%
`0.0%
`0.1%
`0.6%
`6.6%
`1.1%
`3.0%
`0.8%
`7.0%
`0.0%
`1.0%
`4.5%
`2.0%
`0.2%
`2.4%
`0.0%
`0.0%
`0.0%
`0.0%
`100.0%
`
`2012
`0.0%
`0.3%
`0.7%
`7.3%
`0.5%
`3.9%
`3.5%
`11.8%
`0.0%
`1.4%
`23.2%
`0.6%
`0.8%
`1.0%
`7.7%
`0.8%
`0.0%
`1.3%
`0.1%
`5.6%
`0.0 %
`0.1%
`0.5%
`6.6%
`1.0%
`2.9%
`0.6%
`7.2%
`0.0%
`1.0%
`4.4%
`2.6%
`0.2%
`2.5%
`0.0%
`0.0%
`0.0%
`0.0%
`100.0%
`
`2013
`0.0%
`0.4%
`0.6%
`7.3%
`0.4%
`3.9%
`2.4%
`11.1%
`0.0%
`1.2%
`24.7%
`0.5%
`1.0%
`0.8%
`8.0%
`0.4%
`0.5%
`1.3%
`0.1%
`6.0%
`0.0%
`0.1%
`0.4%
`6.3%
`0.9%
`2.9%
`0.5%
`7.6%
`0.0%
`0.6%
`4.7%
`3.1%
`0.1%
`2.5%
`0.0%
`0.0%
`0.0%
`0.0%
`100.0%
`
`2014 Ja n 2015 - Feb 2015
`0.1%
`0.1%
`0.4%
`0.4%
`0.5%
`0.4%
`7.0%
`7.1%
`0.4%
`0.3%
`3.7%
`3.7%
`2.0%
`1.8%
`9.3%
`10.0%
`0.1%
`0.1%
`1.0%
`0.9%
`26.0%
`26.6%
`0.4%
`0.4%
`1.1%
`1.3%
`0.6%
`0.6%
`8.0%
`8.1%
`0.3%
`0.3%
`0.8%
`0.9%
`1.3%
`1.3%
`0.1%
`0.0%
`6.6%
`7.0%
`0.0%
`0.0%
`0.1%
`0.1%
`0.3%
`0.3%
`5.9%
`5.6%
`0.8%
`0.7%
`2.7%
`2.7%
`0.4%
`0.3%
`7.8%
`7.9%
`0.2%
`0.3%
`0.4%
`0.4%
`4 .8%
`4.8%
`3.7%
`3.5%
`0.1%
`0.1%
`2.7%
`2.6%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`100.0%
`100.0%
`
`'""-
`
`Argentum Pharm. v. Research Corp. Techs., IPR2016-00204
`RCT EX. 2136 - 2/3
`
`
`
`AED Market Yearly Sales Volume - April 2007 "' February 2015
`
`UCB Defi ned AED Prod ucts
`Aptiom
`BA NZ EL
`DEPAKOTE
`DEPAKOTE generic
`DEPAKOTE-ER
`DEPAKOTE-ER generic
`DILANTIN
`DILANTIN generic
`FYCOMPA
`KEPPRA-IR
`KEPP RA-IR generic
`KEPPRA-XR
`KEPPRA-XR generic
`LAMICTAL
`LAMICTAL generic
`LAMICTAL-XR
`LAMICTAL-XR GENERIC
`LYRICA
`NEURONTIN
`NEURONTIN generic
`POTIGA
`SABRI L
`TEGRETOL
`TEGRETOL generic
`TEGRETOL-XR
`TEGRETOL-XR generic
`TOPAMAX
`TOPAMAX generic
`TROKENDI XR
`TRILEPTAL
`TRILEPTAL generic
`VIMPAT -taken as 100%
`ZON EGRAN
`ZONEGRAN generic
`Topiramate ER
`Qudexy XR
`
`Total Epilepsy$
`
`Apr 2007 - Dec 2007
`-
`-
`382,250,422
`6,095,837
`250,390,079
`-
`51,367,468
`71,591,041
`-
`767,457,220
`-
`-
`-
`617,589,259
`7,333,217
`-
`-
`30,095,197
`10,166,896
`9,175,393
`-
`-
`20,442,358
`8,800,856
`48,512,474
`41,656,998
`608,551,282
`-
`-
`311,076,655
`35,543,864
`-
`13,645,503
`10,114,688
`-
`-
`-
`3,301,856, 708
`
`2008
`-
`-
`399,436,898
`15,216,364
`375,923,682
`273,960
`65,101,591
`84,454,852
`-
`1,271,571,391
`83,173,062
`6,607,045
`-
`687,753,253
`125,018,863
`-
`-
`53,707,648
`12,305,931
`9,893,416
`-
`-
`24,814,714
`11,231,266
`68,404,526
`59,094,484
`923,696,100
`-
`-
`133,028,781
`92,316,760
`-
`17,416,015
`12,260,188
`-
`-
`-
`4,532, 700, 790
`
`2009
`-
`19,408,528
`90,757,762
`38,722,116
`128,192,251
`83,162,818
`62,236,038
`75,974,892
`-
`459,001,751
`155,918,765
`85,299,507
`-
`220,237,526
`36,466,116
`13,069,655
`-
`57,638,911
`10,904,945
`14,482,718
`-
`1,174,023
`24,061,002
`15,206,599
`52,785,228
`82,846,220
`373,452,309
`28,100,763
`-
`115,151,488
`44,375,103
`35,506,736
`18,001,536
`12,108,887
`-
`-
`-
`2,354,244,193
`
`2010
`-
`42,134,388
`65,220,473
`49,983,973
`60,582,443
`38,318,727
`61,311,285
`67,591,653
`-
`345,891,173
`155,949,044
`144,651, 736
`-
`164,472,267
`12,962,927
`69,974,597
`-
`60,494,323
`11,227,875
`16,673,148
`-
`15,181,908
`24,168,354
`14,607,280
`36,352,919
`99,343,581
`113,492,101
`13,726,671
`-
`92,297,385
`47,333,347
`135,811,664
`19,107,493
`12,611,150
`-
`-
`-
`1,991,473,886
`
`2011
`-
`61,650,484
`61,429,092
`52,819,515
`46,209,830
`26,109,482
`58,648,633
`62,733,302
`-
`277,529,554
`171,224,805
`150,761,459
`4,484,905
`146,643,415
`13,093,648
`106,582,469
`-
`66,187,623
`10,859,748
`20,795,772
`-
`25,744,874
`23,533,970
`16,128,027
`33,626,192
`99,375,627
`100,017,677
`12,078,293
`-
`97,529,630
`39,891,110
`227,482,118
`19,965,813
`10,789,473
`-
`-
`-
`2,043,926,539
`
`2012
`-
`85,797,098
`51,808,554
`35,570,346
`34,234,302
`22,034,799
`53,209,384
`48,146,186
`-
`258,797,030
`169,436,913
`92,383,360
`12,691,463
`136, 703,183
`10,765,721
`152,642,406
`-
`71,051,492
`7,501,143
`19,121,724
`3,822,204
`32,767,161
`20,305,925
`16,235,163
`32,663,121
`95,230,171
`87,916,931
`11,250,005
`-
`113,333,758
`31,959,144
`338,590,602
`19,378,552
`9,232,687
`-
`-
`-
`2,074,580,530
`
`2013
`-
`110,421,332
`48,328,554
`36,105,991
`32,939,947
`90,809,762
`43,384,185
`48,644,028
`-
`254,216,476
`163,785,121
`89,714,406
`15,404,030
`136,087,955
`11,281,560
`104,473,554
`86,564,220
`88,669,905
`7,011,481
`17,602,852
`8,895,051
`93,569,019
`18,435,604
`16,770,268
`37,146,307
`103,288,069
`85,968,487
`10,517,339
`2,361,181
`73,602,933
`42,356,754
`475,172,526
`21,767,163
`20,913,660
`-
`-
`-
`2,396,209,720
`
`2014 Jan 2015 - Feb 2015
`14,340,525
`6,169,802
`144,802,431
`26,399,604
`50,905,350
`7,506,638
`42,444,538
`8,280,564
`34,951,628
`5,337,309
`17,398,231
`132,177,038
`42,402,210
`6,704,603
`59,216,662
`12,004,372
`14,618,071
`3,825,972
`252,291,635
`39,325,060
`157,523,690
`24,757,557
`89,871,167
`14,399,476
`17,402,710
`2,396,673
`132,663,442
`22,998,116
`11,998,677
`1,836,959
`86,794,045
`14,981,810
`82,576,822
`12,925,753
`111,356,014
`19,762,502
`7,149,662
`1,179,833
`17,333,272
`2,835,241
`5,376,963
`754,039
`153,677,838
`32,746,263
`19,713,923
`3,243,056
`49,432,590
`13,108,177
`39,869,432
`6,895,627
`102,425,632
`15,433,390
`79,636,915
`11,868,321
`10,411,380
`1,426,362
`23,388,680
`6,191,773
`67,466,830
`10,747,720
`43,698,066
`6,785,660
`629,001,607
`114,937,422
`25,360,138
`4,610,957
`17,101,879
`2,214,510
`240,971
`245,298
`14,773
`170,666
`-
`-
`2,769,637,208
`482,405,319
`
`Argentum Pharm. v. Research Corp. Techs., IPR2016-00204
`RCT EX. 2136 - 3/3